Skip to main content
. 2022 Aug 26;42(7):1897–1911. doi: 10.1148/rg.220045

Figure 4.

Vaccine-induced axillary lymphadenopathy in a 63-year-old woman with a retropectoral silicone gel implant who underwent screening mammography over 3 different years. (A) Left mediolateral oblique (MLO) mammogram in 2019 shows normal left axillary lymph nodes. (B) Left MLO mammogram in 2021, 2 weeks after she received the first dose of Pfizer-BioNTech SARS-CoV-2 vaccine in the left arm, shows several mildly enlarged superiorly located left axillary lymph nodes (arrow), considered to reflect vaccine-induced lymphadenopathy and assessed as benign (BI-RADS 2). The inferiorly located lymph nodes are unchanged. (C) Left MLO mammogram in 2022 shows normalization of the left axillary lymph nodes.

Vaccine-induced axillary lymphadenopathy in a 63-year-old woman with a retropectoral silicone gel implant who underwent screening mammography over 3 different years. (A) Left mediolateral oblique (MLO) mammogram in 2019 shows normal left axillary lymph nodes. (B) Left MLO mammogram in 2021, 2 weeks after she received the first dose of Pfizer-BioNTech SARS-CoV-2 vaccine in the left arm, shows several mildly enlarged superiorly located left axillary lymph nodes (arrow), considered to reflect vaccine-induced lymphadenopathy and assessed as benign (BI-RADS 2). The inferiorly located lymph nodes are unchanged. (C) Left MLO mammogram in 2022 shows normalization of the left axillary lymph nodes.